Abstract 1175: Identification of novel combination therapies with the LSD1 inhibitor SP-2577 (Seclidemstat) in Ewing's Sarcoma using a complete druggable CRISPR library approach
Samuel Sampson(Translational Genomics Research Institute), Sunil Sharma(Translational Genomics Research Institute), Kevin Drenner(Translational Genomics Research Institute), Trason Thode(Translational Genomics Research Institute), Serina Ng(Translational Genomics Research Institute), Alexis Weston(Translational Genomics Research Institute), Raffaella Soldi(Translational Genomics Research Institute), Mohan R. Kaadige(University of Utah)
Cited by 1
Related Papers
The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer
|PLoS ONE|2020|82
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
|Prostate Cancer and Prostatic Diseases|2016|47
MondoA-Mlx Transcriptional Activity Is Limited by mTOR-MondoA Interaction
|Molecular and Cellular Biology|2014|41
Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells
|Oncotarget|2018|27
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in <i>ARID1A</i> -Mutated Advanced Urothelial Carcinoma
|Molecular Cancer Therapeutics|2018|24